Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas

Seminars in Oncology

Volumn 27, Issue 4 SUPPL., 2000, Pages 402-408

  Swinnen, L J ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; OKT 3; PREDNISONE; RITUXIMAB; VINCRISTINE;

BONE MARROW TRANSPLANTATION; DRUG INDUCED DISEASE; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SEPSIS; VIRUS INFECTION; VIRUS LOAD;

HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE TOLERANCE; LYMPHOMA, AIDS-RELATED; LYMPHOPROLIFERATIVE DISORDERS; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION;

EID: 0033881432     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
2. Are post-transplant lymphomas inevitable?
3. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children
4. Factors affecting survival after orthotopic liver transplantation in infants
5. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiactransplant recipients
6. Cancer in the immunosuppressed organ recipient
7. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
8. Pretransplantation assessment of the risk of lymphoproliferative disorder
9. The changing pattern of posttransplant malignancies
10. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia
11. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
12. Cancer in AIDS
13. Prevalence of Epstein-Barr virus and human papillomavirus in oral mucosa of HIV-infected patients
14. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus
15. Clonal analysis of post-transplant lymphoproliferative disorders, using both episomal Epstein-Barr virus and immunoglobulin genes as markers
16. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations
17. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients
18. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased. EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients
19. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
20. Changes in Epstein-Barr virus load in the peripheral blood following cardiothoracic transplantation
21. Semi-quantitative PCR analysis of genomic EBV DNA post BMT allowsclose surveillance of patients at risk for development of EBV-lymphoproliferative disorders (EBV-LPD) allowing prompt intervention
22. EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients
23. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation
24. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with post-transplant lymphoproliferative disorders
25. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders
26. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients
27. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
28. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
29. Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop
30. Posttransplant T-cell lymphoproliferative disorders - An aggressive, late complication of solid-organ transplantation
31. Post-transplant T-cell lymphoma. Report of three cases and a review of the literature
32. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy
33. The diagnosis and treatment of post-transplant lymphoproliferative disorders
34. Aggressive treatment for post-cardiac transplant lymphoproliferation
35. Clinical characteristics of post-transplant lymphoproliferative disorders
36. Post-transplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression
37. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center
38. BCL-6 gene mutations in post-transplantation lymphoproliferative disorders predict response to therapy and clinical outcome
39. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation
40. Lymphoproliferative disorders and other tumors complicating immunodeficiencies
41. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin
42. Post-transplant lymphoproliferative disorders (PTLD): Clinicopathologic characterization and response to immunomodulatory therapy with interferon-alpha
43. Anti-B-cell monodonal antibodies in the treatment of severe B- cell lymphopioliferative syndrome following bone marrow and organ transplantation
44. Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
45. Rituximab therapy of lymphoproliferative disorders in immunosuppressed patients
46. Humanized anti-CD20 monoclonal antibody (rituximab) in B post-transplant lymphoproliferative disorders (B PTLDs): A retrospective analysis of 32 patients
47. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma: Preliminary report of efficacy, immune reconstitution, and HIV control following therapy
48. Infusions of donor leukocytes to treat Epstein-Barr virus- associated lymphoproliferative disorders after allogeneic bone marrow transplantation
49. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation